Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) EBT Margin (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed EBT Margin for 6 consecutive years, with 22.82% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 496502282.0% to 22.82% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 164.39% through Dec 2025, up 43440588.0% year-over-year, with the annual reading at 164.39% for FY2025, 43440588.0% up from the prior year.
  • EBT Margin for Q4 2025 was 22.82% at 4D Molecular Therapeutics, up from 63172.22% in the prior quarter.
  • The five-year high for EBT Margin was 169852.63% in Q4 2023, with the low at 4965000.0% in Q4 2024.
  • Average EBT Margin over 5 years is 395964.93%, with a median of 11006.72% recorded in 2023.
  • The sharpest move saw EBT Margin crashed -513485263bps in 2024, then soared 496502282bps in 2025.
  • Over 5 years, EBT Margin stood at 27256.52% in 2021, then skyrocketed by 92bps to 2195.83% in 2022, then soared by 7835bps to 169852.63% in 2023, then tumbled by -3023bps to 4965000.0% in 2024, then surged by 100bps to 22.82% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 22.82%, 63172.22%, and 363980.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.